Compare JELD & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | CNTN |
|---|---|---|
| Founded | 1960 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 178.5M |
| IPO Year | 2016 | 2021 |
| Metric | JELD | CNTN |
|---|---|---|
| Price | $1.40 | $2.02 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.93 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 810.6K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $1.75 |
| 52 Week High | $4.92 | $5.27 |
| Indicator | JELD | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 35.67 | 41.64 |
| Support Level | $1.31 | $2.04 |
| Resistance Level | $2.18 | $2.40 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 13.46 | 5.06 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.